Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to initiate a Phase 2 clinical trial of Lucid-MS in patients with multiple sclerosis. The randomized, double-blind, placebo-controlled study represents the first testing of Lucid-MS in people with MS and positions the company among a select group of developers pursuing remyelination strategies.
Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (PAD2). Unlike conventional MS therapies that broadly suppress the immune system, Lucid-MS targets demyelination—the underlying mechanism of the disease—by preventing and reversing myelin degradation. This novel mechanism could offer a complementary or alternative approach for patients who do not respond adequately to existing treatments.
The FDA clearance follows the successful completion of Phase 1 testing in healthy volunteers, where the company reported favorable safety and tolerability. These results support advancing Lucid-MS into a patient population, a critical milestone for any experimental therapy. The Phase 2 trial will assess efficacy and further safety in people with MS, potentially providing key data to guide future development.
In parallel, Quantum BioPharma is collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on a PET imaging tracer designed to quantify demyelination. This research could enhance the ability to measure treatment effects and accelerate drug development not only for Lucid-MS but also for other remyelinating therapies.
The announcement has drawn analyst attention. Rodman & Renshaw recently initiated coverage on Quantum BioPharma with a Buy rating and an $8 price target, reflecting optimism about the company's pipeline. The editorial coverage also placed Quantum BioPharma alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), underscoring the high level of activity in neurology and immunology.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS. Beyond MS, Quantum has invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains full rights to develop similar products for pharmaceutical and medical uses.
For investors, the FDA clearance de-risks the clinical path for Lucid-MS and highlights Quantum BioPharma's potential to address a significant unmet need in MS. If the Phase 2 trial succeeds, Lucid-MS could become a first-in-class treatment, driving substantial value for the company and offering new hope to patients. The latest updates are available in the company's newsroom at https://ibn.fm/QNTM. To view the full press release, visit https://ibn.fm/cwPHa.
